https://www.pharmacytimes.com/view/long-term-follow-up-shows-no-overall-survival-difference-with-parp-inhibitor-maintenance-therapy-in-ovarian-cancer

Data from the ENGOT-OV16/NOVA study show no difference in overall survival (OS) for patients with platinum-sensitive recurrent ovarian cancer who received poly (ADP-ribose) polymerase (PARP) inhibitor niraparib maintenance therapy and those who did not.